Fierce Pharma April 16, 2024
For the first time, Johnson & Johnson has reported sales numbers for its novel multiple myeloma treatment Tecvayli and they indicate that the bispecific, which was approved in October 2022, is off to a solid launch.
In the first quarter, Tecvayli generated $133 million in revenue, compared to $63 million in sales in the first quarter of last year. Also of note was that $101 million of Tecvayli’s first-quarter sales came in the United States, where the B-cell maturation antigen (BCMA) targeting agent can be used after four previous treatments. In Europe, it’s allowed after three other therapies.
Tecvayli’s sales were up sequentially from $112 million in the third quarter of 2023 and $126 million in the fourth quarter.
“We’re...
Today's Sponsors
Today's Sponsor